Prognostic value of the immunohistochemical score based on four markers in head and neck squamous cell carcinoma

Qingqing Xu, Qingjie Li, Zhen Xu, Li-Long Lan, Zan Hou, Juan Liu, Lixia Lu, Yuanyuan Chen, Runzhe Chen, Xin WenFrontiers in Immunology 2023 · DOI

TL;DR

Researchers have developed a novel immunohistochemical (IHC) scoring system using four key protein markers (CK, Ki-67, p16, and p40) that significantly improves the prediction of prognosis in head and neck squamous cell carcinoma (HNSCC) compared to the current standard TNM staging system. This new IHC score, when integrated into a nomogram with other clinical factors, offers a more accurate and personalized approach to patient management.

What Problem Does This Paper Address?

Head and neck squamous cell carcinoma (HNSCC) is a significant global health concern, characterized by high morbidity, poor prognosis, and aggressive behavior. While the TNM (Tumor, Node, Metastasis) staging system is the current standard for predicting HNSCC outcomes, it often falls short due to individual patient heterogeneity, leading to inaccurate prognoses. There's a clear need for more precise and personalized tools to predict disease-free survival (DFS) and guide treatment decisions for HNSCC patients. Immunohistochemistry (IHC), a widely accessible and cost-effective technique, has shown promise in identifying prognostic markers in various cancers, but a comprehensive IHC-based predictive model for HNSCC was lacking.

Methods

The study employed a multi-stage approach:

  • IHC Staining and Evaluation: Standard IHC techniques were used to assess the expression of six candidate protein markers (CK, Ki-67, p16, p40, p53, and p63) in HNSCC tissue samples. Staining intensity was semiquantitatively evaluated by two independent pathologists.
  • IHC Score Development: A Lasso Cox proportional hazards model was utilized to identify the most predictive IHC markers and construct an IHC score. This statistical method is adept at feature selection and building parsimonious models, especially when dealing with a potentially large number of predictors.
  • Model Validation: The developed IHC score was validated in both a training and an independent validation cohort. Predictive accuracy was assessed using the concordance index (C-index) and Kaplan-Meier survival analysis.
  • Nomogram Construction: A nomogram, a graphical tool for predicting outcomes, was built by integrating the established IHC score with other significant clinicopathological factors identified through Cox regression analysis. Calibration curves were used to assess the agreement between predicted and observed survival.

Datasets

The study utilized data from 666 patients with de novo HNSCC collected from Sun Yat-Sen University Cancer Center.

  • Training Cohort: 402 patients.
  • Validation Cohort: 264 patients.

The data included histopathological confirmation, patient demographics (age, sex), lifestyle factors (smoking and drinking status), tumor location, and TNM stage (8th edition). No new benchmark datasets were introduced; the study focused on leveraging existing patient data.

Key Insights and Ideas

  • Four Markers are Key: The study identified a specific combination of four IHC markers – CK, Ki-67, p16, and p40 – as being most effective in predicting HNSCC prognosis, outperforming models using all six initial markers. This highlights the power of targeted biomarker selection.
  • IHC Score Outperforms TNM: The developed IHC score demonstrated superior predictive power for disease-free survival compared to the established TNM staging system (8th edition), suggesting a more nuanced understanding of patient risk.
  • Independent Prognostic Factor: The IHC score was confirmed as an independent predictor of prognosis, even after accounting for other critical clinicopathological variables. This underscores its robustness.
  • Nomogram for Practical Application: The creation of a nomogram integrating the IHC score with clinical factors provides a user-friendly, quantitative tool for clinicians to estimate individual patient prognosis, facilitating personalized care.

Key Results

  • High Predictive Accuracy: The IHC score achieved high C-index values (0.800 for training, 0.824 for validation), indicating strong predictive accuracy for survival.
  • Superior to TNM: The area under the ROC curve (AUC) for the IHC score in predicting one- and three-year DFS was significantly higher than that of the TNM stage in both training and validation cohorts. For instance, the one-year DFS AUC for the IHC score was 0.787 (training) and 0.857 (validation), compared to 0.688 and 0.611 for the TNM stage, respectively.
  • Independent Predictor: In multivariate Cox regression, the IHC score was a significant independent factor for predicting DFS, with hazard ratios of 8.395 (training) and 13.613 (validation).
  • Nomogram Performance: The nomogram demonstrated good predictive performance, with C-index values of 0.803 (training) and 0.800 (validation), and calibration curves showed good agreement between predicted and observed survival.

Limitations and Future Work

  • Single-Institution Study: The data were collected from a single institution, which could limit the generalizability of the findings. The authors suggest that larger, multi-institutional studies are needed to confirm these results.
  • Retrospective Analysis: The study was retrospective, which may introduce certain biases.
  • Future Directions: The authors propose that prospective studies are necessary to further validate the hypothesis and the clinical utility of the developed nomogram. They also emphasize that combining the IHC score with the TNM system can facilitate more individualized patient consultation and care.

Summary updated

Abstract

The IHC score was more accurate than the eighth edition of the TNM system in predicting HNSCC prognosis. Therefore, combining the two methods can facilitate individualized patient consultation and care.
BibTeX
@inproceedings{xu2023prognostic,
  author = {Qingqing Xu and Qingjie Li and Zhen Xu and Li-Long Lan and Zan Hou and Juan Liu and Lixia Lu and Yuanyuan Chen and Runzhe Chen and Xin Wen},
  title = {{Prognostic value of the immunohistochemical score based on four markers in head and neck squamous cell carcinoma}},
  booktitle = {Frontiers in Immunology},
  year = {2023},
  doi = {10.3389/fimmu.2023.1076890},
}
Figure